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Human papillomavirus (HPV) is closely associated with cervical cancer that the incidence
of this tumor is regarded as a surrogate marker for HPV infection in countries lacking epi-
demiological studies. HPV is also implicated in subsets of anogenital and oropharyngeal
cancers. Although cervical cancer is the third most common cancer in women worldwide,
its reported incidence is low in Saudi Arabia, ranking number 12 between all cancers in
females and accounts only for 2.4% of all new cases, despite the lack of national screen-
ing programs. However, the limited available studies from Saudi Arabia indicate that HPV
prevalence and genotypes’ distribution in invasive cervical cancer show similar pattern as
in the world. Cytology screening (Pap smear) and HPV vaccinations are the two preven-
tive measures against cervical cancer. The two available vaccines are effective against the
two most common HPV genotypes (HPV-16 and -18). Since 92% of cervical tumors in the
Kingdom are infected with HPV of which 78% are HPV-16 and -18 genotypes, vaccination
is expected to protect against more than two-third of cervical cancers in Saudi Arabia.
Nevertheless, due to its low incidence (2.1/100,000 women), a proper cost-effectiveness
analysis is required to justify the implementation of a costly vaccine bearing in mind that
HPV could potentially be associated with about 3% of all cancers. However, further studies
are needed to ascertain the real prevalence of HPV at the population level at large, its asso-
ciation with various types of cancers, and also the impact of local tradition and emerging
behavioral trends that could affect HPV transmission and consequently the effectiveness
of applying national vaccination program.
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INTRODUCTION
Human papillomavirus (HPV) has been overwhelmingly associ-
ated with cervical cancer that the incidence of this malignancy is
deemed as surrogate indicator of HPV infection in countries lack-
ing epidemiological studies. This can easily be justified because the
worldwide HPV prevalence in cervical cancer has been estimated
between 85 and 99% (1, 2). According to the International Agency
for Research on Cancer, report GLOBOCAN 2008, cervical can-
cer is the third most common cancer in women worldwide, and
the seventh overall, with an estimated 530,000 new cases in 2008
(3). More than 85% of the global burden occurs in developing
countries, where it accounts for 13% of all female cancers. Age
standardized rates show that cervical cancer is the second most
common cancer in women in less developed countries while it
ranks number 7 in developed countries. This is due to the lack of
proper screening program (4). Pap smear screening, which identi-
fies cytological abnormalities of the cervical transformation zone,
has helped reducing cervical cancer incidence and mortality rates
by 70% in developed countries (5).
HPV INFECTION AND RELATED CANCERS
Human papillomavirus infection is common particularly in sex-
ually active period of age. Reported estimates of incident HPV
infection among initially negative women have reached as high
as 60% over a 5-year follow-up period (6). The population-wide
prevalence of HPV in women varies among studies and countries
from 1.5 to 39% and closely reflects age and sexual activity (7–9).
In addition, HPV infection has also been implicated in other can-
cers such as 90% of anal cancers and a smaller subset (<50%) of
oropharyngeal, penile, vaginal, and vulvar cancers. In total, HPV
may account for 5.2% of the worldwide cancer burden (10).
In contrast to the global view, the incidence of cervical cancer
is very low in Saudi Arabia, ranking number 12 between all can-
cers in females and accounts only for 2.4% of all new cases (11),
despite the lack of national screening programs. The incidence
rate is extracted from the Saudi Cancer Registry (SCR), which is
a population-based registry developed in 1992. It was established
under the jurisdiction of the Ministry of Health and commenced
reporting cancer cases from 01 January 1994. Although it relies on
the collaboration of 500 governmental and private hospitals,physi-
cian’s offices, cancer treatment centers, and pathology laboratories
located throughout the country, full coverage of all cancer cases
cannot be ascertained. Nevertheless, in view of the lack of national
screening programs, the actual reason for this low incidence is
unknown. The closed society and standards of mores could reduce
women’s exposure to HPV infection (12–15). Although cervical
cancer is both preventable and curable, due to the lack of accessible
screening in Saudi Arabia, most cases are presented at advanced
stages (16, 17), that require extensive chemo-radiation therapy.
This is due to the lack of proper screening program (4).

























































Alsbeih HPV and related cancers in KSA
Data concerning the prevalence of HPV infection, HPV geno-
types, and its relationship with cervical cancer are globally scarce
in Saudi Arabia. Studies profiling Pap smears examined at Uni-
versity Hospitals have revealed precursor lesions of cervical cancer
(14, 18–20). A study combining HPV detection with Pap test in
100 women undergoing voluntarily cervical cytological screening
have found 6% HPV-positive cases that consisted of 5% high-
risk and 1% low risk HPV (21). This percentage has further been
confirmed in a larger, more recent study including 485 women
seeking general gynecologic care at King Abdulaziz University Hos-
pital in western region of Saudi Arabia (22). In contrast to these
low risk settings, a study performed on 120 women attending
routine gynecological examination in a hospital-based commu-
nity, with dominant human components that has international
acquaintances, has reported a prevalence of 31.6% infection with
HPV-16/18 (23). In this study, none of the seven subjects with
abnormal cytology had progressed to cervical intraepithelial neo-
plasia (CIN3) after 4 years of follow-up; suggesting non-persisting
infection (24, 25). However, these studies were all confined to
communities revolving around major hospitals and had included
limited number of subjects. In addition, as local tradition lim-
its sexual activities to marriage with no studies of the impact of
travel on infection transmission considering the large portion of
Saudi young generation traveling abroad for studies, business, and
leisure, the real epidemiological prevalence of HPV infection in
native Saudi population is still unknown.
The magnitude of the association between HPV infections and
genotypes as causative agent of cervical cancer has been recently
evaluated in limited number of patients in two independent stud-
ies from the same institute (26, 27). The first study had included
100 paraffin-embedded cervical biopsies with histopathologically
proven cervical cancer. By histology,82% were squamous cell carci-
noma and 18% were adenocarcinoma of the cervix. Eleven patients
had reported other unidentified past cervical infections and only
six had prior screening. HPV detection and genotyping was car-
ried out using the Linear Array kit (Roche Diagnostic) that enables
the concomitant detection of 37 mucosal HPVs including 13 most
common high-risk viruses. Results showed that 89% were positive
for HPV infection. By histopathology, 93% of squamous cell car-
cinomas and 72% of adenocarcinomas are HPV positive. In total,
11 different HPV genotypes were detected, 8 of which (16, 18,
31, 39, 45, 51, 59, 73) are commonly classified as high-risk (87%)
and 3 (6, 64, and 70) are classified as low risk (2%) HPVs. Thus,
the prevalence of high-risk genotypes was 97.8% of HPV-positive
tumors, which is comparable to the regional results obtained by
Darnel et al. involving 44 Syrian women with invasive cervical can-
cer (28). The frequencies of the different HPV genotypes detected
are summarized in (Table 1).
In agreement with other studies, the most common HPV geno-
type was HPV-16 (29) with a prevalence of 65.2% compared to
54.4% in the world (30). The following most common genotypes
by decreasing prevalence were: HPV-31 (7.9%), HPV-45 (6.7%),
HPV-18 (3.4%), and HPV-73 (2.3%). The HPV genotypes (6, 39,
51, 59, 64, and 70) had an estimated prevalence of 1.1% each.
Co-infections implicated HPV-16 with HPV-18 (6.7%), HPV-39,
HPV-51, and HPV-70 (1.1% each), and HPV-45/59 (1.1%). With
double infections, the two most common HPV genotypes were 16
Table 1 | Prevalence of different HPV genotypes in two studies
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SINGLE INFECTION
HPV-6 LR 1.1
HPV-16 HR 65.2 63.4
HPV-18 HR 3.4 11.1
HPV-31 HR 7.9 2.2
HPV-33 3.3














LR, low risk; HR, high-risk.
and 18 with an estimated overall prevalence of 70% of all patients
and 78.7% of HPV-positive tumors. This is comparable to the
prevalence observed in Europe (74.5%), North America (76.5%),
and in the whole-world (70.9%). However, these results seem to
be different from those obtained in another Middle Eastern coun-
try where the most common HPV genotype was 33, which was
detected at low prevalence in one of the two referenced study
in Table 1, followed by 16 and 18 (28). Interestingly, as it had
been described in the literature (25, 31), the two most common
HPV genotypes (16 and 18) were more frequent in younger age
group, and caused cervical cancer to occur 5 years earlier than
other HPV infected patients. Furthermore, age-specific HPV dis-
tribution in Saudi cervical cancer patients showed a bimodal curve
with a first peak at younger ages (41–45 years) and a relative
rebound at older ages (56–60 years) as it has been described in
other population (32).
The second study included 90 patients with cervical can-
cer and had essentially reached similar results using polymerase
chain reaction amplification methods with two common primers,
MY09, MY11 and GP5+, GP6+ that amplify a wide range of
HPVs of which isolates were genotyped using DNA sequencing
and reverse line blot hybridization assay to identify the high-risk
HPV genotypes (27). Results showed that 95.5% were HPV pos-
itive. The most common HPV genotype detected was HPV-16
(63.4%), HPV-18 (11.1%), HPV-45 (4.5%), HPV-33 (3.3%), and

























































Alsbeih HPV and related cancers in KSA
HPV-31, HPV-52, HPV-53, HPV-58, HPV-59, and HPV-66 with
2.2% prevalence rate each (Table 1). Both studies concluded that
the results obtained in Saudi cervical cancer patients are compa-
rable to international rates, namely: (1) the prevalence of HPV
infection (89–96%) is in range of the published worldwide esti-
mates of 85–99% (1, 2); and (2) the most common genotypes are
the high-risk HPV-16 and -18 that affect together 74.5–78.7% of
all HPV-positive patients (Figure 1).
In North America, it was noted that, although there has been
significant reduction of the incidence of head and neck cancers as
a result of the anti-smoking campaigns since the late 80s, there was
a significant increase in the incidence of oropharyngeal squamous
cell carcinomas in young (40–55 years) specifically in the tonsils
and the base of the tongue where most of these patients are not
alcohol or tobacco consumers (33). About 60% of these tumors
were found positive for HPV-16, the same type that leads to HPV-
associated anogenital cancers. Interestingly, the prevalence of HPV
infections in the oral cavity is significantly higher among men than
women. In a systematic meta-analysis, Kreimer et al. have reviewed
60 eligible studies that included 5,046 cases of squamous cell carci-
nomas of the head and neck (34). HPV was prevalent in 35.6% of
oropharyngeal, in 23.5% of oral, and in 24% of laryngeal cancers.
HPV-16 was by far the commonest subtype in all HPV-positive
cancers (87% of oropharyngeal, 68% of oral, and 69% of laryngeal
cancers). HPV-18 was the next most common subtype.
So far, the prevalence of HPV infection in anal, penile, vagi-
nal, vulvar, and oropharyngeal cancers has not yet been explored
in Saudi Arabia. Nevertheless, it is important to include these
forecasted potential when discussing the eventual impact of HPV
vaccines in a society. In fact, the extrapolation of these rough esti-
mated percentages of HPV-positive anogenital (96%) and head
and neck (30%) cancers in Saudi Arabia is given in Figure 2. In
total, potential HPV-related cancers would represent about 3% of
all cancers in both genders. In addition, HPV has more recently
been suspected to be implicated in subgroups of colorectal and
breast malignancies, however; these studies remain inconclusive,
particularly that some experts in the field still do not support such
a role in view of the inadequate evidence.
Acknowledging that detection of HPV infection in head and
neck cancers remains lacking with no published report to date
from Saudi Arabia, few studies had looked at this potential in
some other types of tumors such as ocular and prostatic cancers.
Karcioglu and Issa had examined the presence of HPV-16/18 in
96 paraffin-embedded external ocular tissues with neoplastic and
non-neoplastic lesions and 19 conjunctiva samples free from overt
disease (35). They reported HPV positivity in 57% of in situ squa-
mous cell carcinoma, in 55% of invasive squamous cell carcinoma,
in 20% of climatic droplet keratopathy, in 35% of scarred corneas,
and in 32% of normal conjunctival tissue obtained during routine
cataract extractions. They concluded that HPV is detectable not
only in epithelial neoplasms of the ocular mucous membrane but
also in non-neoplastic lesions as well as in apparently healthy con-
junctiva. Gazzaz and Mosli had explored the possibility of finding
HPV infection in prostatic tissues of 56 patients presenting with
benign prostatic hyperplasia (BPH) or prostate cancer (36). The
results showed that all the prostatic biopsies were negative for HPV
DNA as assessed by the hybrid capture 2 technology that can detect
13 carcinogenic types of HPV infection, and differentiate between
the 2 HPV groups, the low and the high/intermediate risk types.
The authors concluded that it is unlikely that HPV enhance the
risk of prostate cancer.
PREVENTION AND HPV VACCINES
Prevention of cervical cancer is provided by HPV screening and
vaccination, which is an effective measure in many infectious dis-
eases (24, 25). Vaccines were developed against HPV infection to
prevent cervical cancer and probably other HPV-related diseases
(37). Two types, a bivalent (Cervarix) vaccine that protect against
HPV-16 and -18 and a quadrivalent (Gardasil) that is effective
against HPV-6, -11, -16, and -18 are being widely introduced in
western countries (38, 39), and promising new broad-spectrum
HPV vaccines are in development (40). The short term results
FIGURE 1 |The prevalence of HPV infection and genotypes distribution in cervical cancer in Saudi Arabia compiled from two published studies (26, 27).
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FIGURE 2 | Burden of potentially HPV-mediated cancers in Saudi
Arabia.
showed nearly complete efficacy against cervical cytological abnor-
malities, precancerous lesions, and even genital warts in the case
of the quadrivalent vaccine (37, 38).
In principle, the vaccines could be applicable in Saudi Arabia
since the incidence of HPV infection in invasive cervical cancer is
very high (89–96%) and comparable to the whole-world (85–99%)
and that about 75% are HPV-16/18 genotypes (Figure 1), which
are covered by both currently available vaccines. Therefore, in
theory vaccination is expected to protect against more than three-
quarters of cervical cancers in Saudi Arabia as it has been estimated
worldwide (38). In contrast, the incidence of cervical cancer is very
low in Saudi Arabia, forming only 2.4% of all females’ cancers.
From an expenditure point of view, an expert cost-effectiveness
analysis that takes into consideration the particular incidence of
cervical cancer in the country, is required to justify the implemen-
tation of a costly national vaccination program (41). The current
information from the SCR and the WHO/ICO indicates that the
incidence of cervical cancer in Saudi Arabia is 2.1/100,000 women.
This rate is at the threshold of the best performance that cytol-
ogy screening (Pap smear) can offer and is much lower than the
two available vaccines against HPVs can achieve at 9/100,000 for
Cervarix and 14/100,000 for Gardasil (37, 38).
Although cost-effectiveness criteria may vary between coun-
tries, a preliminary evaluation would suggest that there is no reason
for public health to institute either screening or vaccination if
Saudi Arabia truly has such a low incidence of cervical cancer.
Therefore, theoretically, some might argue that implementing a
national vaccination program may not sensibly decrease the inci-
dence of cervical cancer at the population level because it is already
very low. In addition, if all 10–14 years old girls are to be vacci-
nated in Saudi Arabia (1,006,745 girls× 3 shots/girl), this would
be a burden on health system and may not be cost-effective in
comparison with other health priorities. Nevertheless, there may
be specific individual benefits that screening or vaccination may
offer for selected women, who would be identified upon careful
analysis of the frequency of cervical cancer in groups at risk for
HPV infection or women well-informed about the risk and vol-
untarily wish to be vaccinated. However, taking into consideration
the projection of all potentially HPV-associated tumors outlined
in Figure 2, in theory, the vaccination is expected to protect about
3% of cancer patients in Saudi Arabia, which would be, from
an expenditure standpoint, still require proper cost-effectiveness
evaluation in view of the incidence of head and neck [excluding
nasopharyngeal carcinoma that would rather be associated with
Epstein–Barr virus (EBV) infection] and anogenital cancers in the
country. In addition, many DNA vaccines are being developed
for the treatment of HPV-16 induced malignancies (42). Most
of these vaccines consist of a fusion of E6 or E7 with a “carrier-
protein” to generate highly immunogenic E6- or E7-directed DNA
vaccines. These vaccines can be used to treat HPV-positive cancers
to improve outcome.
Currently, the vaccines are available in major hospitals in Saudi
Arabia and are offered with or without fee to requesting girls upon
physician’s prescription. Family physicians should also be pro-
vided with objective information regarding the HPV vaccine so
they would recommend the vaccine to their patients (43). Parents’
involvement is a significant factor in decision making since cur-
rent practice recommends vaccination to be carried out on minors
and young age (9–26 years old) for best efficacy. Hence, educating
families and medical staff on the vaccines is important to recon-
cile with religious values and beliefs bearing in mind that vaccines
at large have saved more lives than any medical treatment ever
developed.
CONCLUSION
Beside the salient difference of having very low incidence of cer-
vical cancer in Saudi Arabia, the involvement of HPV infection in
this malignancy is comparable to the rest of the world with HPV-
16 and -18 being the two most common genotypes and account
together for three-quarters of HPV infection. Although vaccina-
tion against HPV would protect three-quarters of cervical cancer
patients, the currently reported low incidence and the high cost
of the vaccine would make it not-cost-effective in the Kingdom
of Saudi Arabia. However, to ascertain or refute these conclusions,
further studies are needed to find out the real prevalence of HPV
at the population level at large, its association with various types
of cancers, and also the impact of local tradition and emerging
behavioral trends that could affect HPV transmission.
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